Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Connect Biopharma Holdings Limited is a biotechnology business based in the US. Connect Biopharma shares (CNTB) are listed on the NASDAQ and all prices are listed in US Dollars. Connect Biopharma employs 62 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$17.17|
|52-week range||$14.02 - $29.00|
|50-day moving average||$21.94|
|200-day moving average||$19.65|
|Wall St. target price||$29.31|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-7.98|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||-6.43%|
|1 month (2021-09-16)||-16.45%|
|3 months (2021-07-16)||-21.95%|
|6 months (2021-04-16)||-0.58%|
|1 year (2020-10-12)||N/A|
|2 years (2019-10-12)||N/A|
|3 years (2018-10-12)||N/A|
|5 years (2016-10-12)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-14.75%|
|Return on equity TTM||-9999999%|
|Market capitalisation||$1.1 billion|
TTM: trailing 12 months
There are currently 854,558 Connect Biopharma shares held short by investors – that's known as Connect Biopharma's "short interest". This figure is 0.3% up from 851,674 last month.
There are a few different ways that this level of interest in shorting Connect Biopharma shares can be evaluated.
Connect Biopharma's "short interest ratio" (SIR) is the quantity of Connect Biopharma shares currently shorted divided by the average quantity of Connect Biopharma shares traded daily (recently around 53915.331230284). Connect Biopharma's SIR currently stands at 15.85. In other words for every 100,000 Connect Biopharma shares traded daily on the market, roughly 15850 shares are currently held short.
To gain some more context, you can compare Connect Biopharma's short interest ratio against those of similar companies.
However Connect Biopharma's short interest can also be evaluated against the total number of Connect Biopharma shares, or, against the total number of tradable Connect Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Connect Biopharma's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Connect Biopharma shares in existence, roughly 10 shares are currently held short) or 0.0657% of the tradable shares (for every 100,000 tradable Connect Biopharma shares, roughly 66 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Connect Biopharma.
Find out more about how you can short Connect Biopharma stock.
We're not expecting Connect Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.